Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIIB randomized double-blind study of subcutaneous versus intravenous abatacept in rheumatoid arthritis
2007-005434-37Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2008
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of abatacept in rheumatoid arthritis (RA) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: ACR 20 response at 6 months. Started May 2008; status: completed.
02
Drugs
abatacept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2007-005434-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005434-37.